Table 3.

Echocardiographic characteristics and serum N-terminal-prohormone of brain natriuretic peptide level of both groups after about 2-year follow-up

	Alendronate treated	Nontreated	P#	Adjusted mean difference	L	U	Adjusted P$
NT-pro-BNP	881.48±519.63	1185.12±591.42	0.009	−384.89	−588.36	−181.41	<0.001
LVDD	46.0±4.59	47.39±3.92	0.18	−1.17	−2.10	−0.23	0.015
LVEF	56.62±4.24	54.48±5.94	0.18	2.29	0.25	4.32	0.028
IVS	11.81±1.64	12.30±1.42	0.21	−0.86	−1.27	−0.44	<0.001
MG	25.28±8.95	29.39±9.14	0.02	−2.14	−3.63	−0.64	0.006
PG	44.70±14.51	51.21±11.45	0.04	−4.54	−6.16	−2.92	<0.001
AVA	1.37±0.33	1.34±0.30	0.69	0.12	0.05	0.19	0.001
Delta-AVA	−0.09±0.17	−0.23±0.13	0.001	0.129	0.054	0.204	0.001

BMI=Body mass index; SD=Standard deviation; NT-Pro BNP=N-terminal-prohormone of brain natriuretic peptide; LVDD=Left ventricular diastolic diameter; LVEF: Left ventricular ejection fraction; IVS=Interventricular septum; MG=Mean gradient; PG=Peak gradient; AVA=Aortic valve area. Data are expressed as mean±SD. ^#based on t-test; ^$Adjusted for age, BMI, follow-up time, and baseline measurements using analysis of covariance; L=95% confidence interval lower bound; U=95% confidence interval upper bound